Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Rosuvastatin Stories

2010-06-21 07:00:00

MONTGOMERY, Ala. and INDIANAPOLIS, June 21 /PRNewswire-FirstCall/ -- Kowa Pharmaceuticals America, Inc., and Eli Lilly and Company (NYSE: LLY) today announced that LIVALO® (pitavastatin) tablets is now available in retail pharmacies throughout the United States. LIVALO, a statin medication approved by the U.S. Food and Drug Administration (FDA) in August 2009 is indicated for adults as an adjunctive therapy to diet for the treatment of primary hyperlipidemia or mixed...

2010-05-26 07:00:00

ATLANTA, May 26 /PRNewswire/ -- Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., announced today that the investigational new drug PSD502, a topical metered dose spray which is being developed for the treatment of primary premature ejaculation (PE), will be the subject of five clinical presentations early next month. These data will be presented at the American Urological Association's (AUA) 2010 Annual Meeting May 29 to June 3 in San Francisco. The...

2010-05-05 17:27:00

NEW YORK, May 5 /PRNewswire-FirstCall/ -- Pfizer's Viagra and AstraZeneca's Nexium took the top-two slots on the new L2 Digital IQ Index for pharmaceutical brands, a first-of-its kind measurement of the digital competence of 51 pharma brands across eight therapeutic categories, designed to provide an actionable metric to optimize pharmaceutical digital ROI. The ranking, created by think tank L2 in partnership with leading media agency PHD Network, evaluated pharmaceutical brands'...

2010-04-27 01:00:00

LONDON, April 27 /PRNewswire/ -- CRESTOR(TM) (rosuvastatin) has been approved in nineteen countries within the EU for the prevention of major cardiovascular events in patients who are at high risk* of having a first cardiovascular event. To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/astrazeneca/43661/ (Photo: http://www.newscom.com/cgi-bin/prnh/20100427/MM93313) This new indication is based on subgroup data from the landmark...

2010-04-21 07:00:00

WALTHAM, Mass., April 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a dyslipidemia drug that is dosed once a week would earn 40 percent patient share in the U.S., according to surveyed U.S. primary care physicians (PCPs). In contrast, in Europe, such a drug would earn 23 percent patient share, according to surveyed European physicians. These estimated patient shares are comparable to shares...

2010-03-30 07:02:00

WILMINGTON, Del. and ABBOTT PARK, Ill., March 30 /PRNewswire-FirstCall/ -- AstraZeneca and Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) for the New Drug Application (NDA) for CERTRIAD(TM) (rosuvastatin / fenofibric acid delayed release) Capsules. The companies are currently evaluating the CRL, will continue discussions with the FDA to determine next steps with respect to the CERTRIAD NDA and will respond to the...

2010-03-19 10:00:00

Highest approved dose of cholesterol-lowering medication could cause harm to muscles SILVER SPRING, Md., March 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned patients and healthcare providers about the potential for increased risk of muscle injury from the cholesterol-lowering medication Zocor (simvastatin) 80 mg. Although muscle injury (called myopathy) is a known side effect with all statins, today's warning highlights the greater risk of developing...

2010-03-02 07:30:00

OSAKA, Japan, ATLANTA and ANN ARBOR, Mich., March 2 /PRNewswire/ -- Shionogi & Co., Ltd. and QuatRx Pharmaceuticals Company, a privately-held pharmaceutical company, today announced that they have entered into a worldwide license agreement to develop and market ospemifene, a selective estrogen receptor modulator ("SERM"). Under the terms of this agreement, Shionogi will have worldwide marketing rights to ospemifene. QuatRx will receive an up-front payment of $25 million and is eligible...

2010-02-08 18:09:00

WILMINGTON, Del., Feb. 8 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the US Food and Drug Administration (FDA) has approved CRESTOR® (rosuvastatin calcium) to reduce the risk of stroke, myocardial infarction (heart attack) and arterial revascularization procedures in individuals without clinically evident coronary heart disease but with an increased risk of cardiovascular disease (CVD) based on age (men greater than or equal to 50 and women...

2009-12-15 16:58:00

WILMINGTON, Del., Dec. 15 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) today voted 12 yes, 4 no, and 1 abstention that AstraZeneca has established sufficient benefit to offset the observed risks to support the use of CRESTOR® (rosuvastatin calcium) in individuals meeting the following criteria: Men greater than or equal to 50 years, women greater than or equal to 60 years; Fasting LDL...